A drug developed in Rio de Janeiro has just cleared a significant hurdle
Em laboratórios da Universidade Federal do Rio de Janeiro, pesquisadores passaram mais de duas décadas estudando uma proteína que o próprio corpo humano produz — a laminina — como possível caminho para reparar lesões na medula espinhal. Agora, a Anvisa autorizou o primeiro ensaio clínico da polilaminina em seres humanos, um marco que transforma anos de ciência silenciosa em esperança concreta para pacientes que, até hoje, dispõem de poucas alternativas terapêuticas. A aprovação não é uma promessa de cura, mas é o reconhecimento de que a pergunta merece ser feita em voz alta — e com rigor.
- Lesões medulares completas roubam o movimento de forma abrupta e, na maioria dos casos, definitiva — e a medicina ainda oferece respostas muito limitadas para quem as sofre.
- A polilaminina chamou atenção porque, em testes preliminares não controlados, alguns pacientes recuperaram parcialmente — e outros de forma mais substancial — a capacidade de se mover após o trauma.
- A janela de 72 horas para inclusão no estudo revela a lógica do tratamento: o medicamento precisa agir antes que o tecido cicatricial se consolide e torne a lesão irreversível.
- Cinco voluntários adultos com lesões torácicas completas receberão dose única do fármaco durante cirurgia, num ensaio de Fase 1 cujo objetivo central é confirmar segurança, não eficácia.
- A parceria entre a UFRJ e a farmacêutica Cristália sinaliza que a ciência avançou o suficiente para atrair investimento privado — e a aprovação por via acelerada da Anvisa reforça a urgência reconhecida pelo regulador.
- Se a segurança for confirmada, o caminho para ensaios de eficácia — e eventualmente para vias regulatórias expeditas — estará aberto, mantendo acesa a esperança de pacientes e famílias.
Um medicamento desenvolvido no Rio de Janeiro acaba de receber autorização da Anvisa para seu primeiro teste em seres humanos. A polilaminina, composto baseado em uma proteína naturalmente presente no organismo, foi criada por pesquisadores da UFRJ com o objetivo de tratar lesões medulares em sua fase mais aguda. A aprovação encerra mais de duas décadas de trabalho laboratorial e abre uma nova etapa — mais visível, mais exigente e carregada de expectativa.
O ensaio clínico de Fase 1 terá escopo restrito e desenho cuidadoso: cinco adultos com lesões medulares torácicas completas, ocorridas há no máximo 72 horas, receberão dose única do fármaco aplicada diretamente na região afetada durante procedimento cirúrgico. A escolha dessa janela temporal não é arbitrária — os pesquisadores acreditam que a eficácia do composto depende de sua aplicação antes que o tecido cicatricial se forme e consolide o dano.
O que tornou a polilaminina digna de investigação formal foram resultados obtidos em testes anteriores, informais e não controlados, nos quais alguns pacientes apresentaram recuperação parcial do movimento e outros recuperaram função de forma mais expressiva. Esses achados, ainda que preliminares, foram suficientes para convencer o regulador a aprovar o avanço por uma via acelerada reservada a tecnologias de relevância estratégica — um reconhecimento implícito de que lesões medulares constituem uma crise médica sem soluções adequadas.
O desenvolvimento do fármaco conta com parceria entre a universidade pública e a farmacêutica Cristália, que também financia o projeto. Caroline Alves, à frente da fundação de apoio à pesquisa, destacou que a aprovação não representa uma virada repentina, mas a colheita de um investimento longo e persistente em ciência pública. Os ensaios devem começar em semanas, após a definição dos hospitais participantes. Caso a Fase 1 confirme a segurança do composto, o caminho estará aberto para testar sua eficácia em grupos maiores — e, eventualmente, para acelerar sua chegada aos pacientes que mais precisam.
A drug developed in Rio de Janeiro has just cleared a significant hurdle on its path to human testing. Brazil's health regulator, Anvisa, has given the green light for the first clinical trial of polylaminin, an experimental treatment designed to repair spinal cord injuries in their earliest stages. The approval marks a turning point for a research program that has been quietly advancing for more than two decades.
The work began at the Federal University of Rio de Janeiro, where researchers have been studying polylaminin as a potential therapy for patients whose spinal cords have been recently damaged. The compound is based on laminin, a protein that naturally occurs in the body and plays a role in regenerating nerve connections. What makes this moment significant is that the researchers have moved from laboratory work to actual human trials—a transition that happens rarely and only when preliminary evidence suggests real promise.
The first phase of testing will be modest in scope but carefully designed. Five adult volunteers with complete spinal cord injuries in the thoracic region—injuries that occurred no more than 72 hours before enrollment—will receive a single dose of the drug. The treatment will be administered directly to the damaged area during surgery. This narrow window is deliberate: the researchers believe the drug works best when applied immediately after trauma, before scar tissue forms and hardens the injury site.
What makes polylaminin noteworthy is what happened in earlier, informal testing. Some patients who received the substance shortly after their injuries experienced partial recovery of movement, and a few regained function more substantially. These results, while preliminary and uncontrolled, were striking enough to convince Anvisa that the drug warranted formal clinical investigation. The regulatory approval came through an expedited pathway created specifically for technologies deemed strategically important—a recognition that spinal cord injuries represent a medical crisis with few existing solutions.
The drug being tested is a standardized version developed through a partnership between the university researchers and Cristália, a pharmaceutical company that is also funding the work. This collaboration between public research and private industry is typical of how experimental medicines move toward patients. The company's involvement signals confidence that the science is sound enough to warrant commercial investment.
If this first phase confirms that polylaminin is safe—the primary goal of Phase 1 trials—the research can advance to test whether it actually works. That next step would involve larger groups of patients and longer follow-up periods to measure whether the drug genuinely restores function. Given the severity of spinal cord injuries and the scarcity of effective treatments, the drug could eventually qualify for expedited regulatory pathways that would accelerate its journey to patients.
Caroline Alves, who leads the research foundation that has supported this work, framed the approval as validation of long-term investment in public science. She noted that this is not a sudden breakthrough but the culmination of sustained funding and research at public universities—the kind of patient, unglamorous work that often precedes medical advances. The trials are expected to begin within weeks, once the participating hospitals are finalized. For patients and families facing spinal cord injuries with no good options, the next phase of this research will be watched closely.
Citas Notables
We are talking about research built over many years, with continuous support for science conducted in public universities. Seeing this knowledge advance to a clinical study is an achievement for Rio de Janeiro and, above all, for people who today have no treatment options.— Caroline Alves, president of FAPERJ
La Conversación del Hearth Otra perspectiva de la historia
Why does the 72-hour window matter so much? Why not treat someone months or years after their injury?
Scar tissue forms quickly after a spinal cord injury. Once it hardens, the nerve fibers can't regenerate through it. The drug seems to work by supporting nerve regrowth before that scar becomes a permanent barrier. It's a narrow window, but it's the one where the biology is still responsive.
Five volunteers is a very small number. How much can researchers actually learn from that?
Phase 1 isn't about proving the drug works. It's about proving it doesn't harm people. With five carefully selected patients, they can watch for safety signals, measure how the body tolerates the drug, and see if there are any unexpected reactions. If something goes wrong, they'll know quickly. If it's safe, they move forward.
The source mentions that some patients in earlier testing recovered movement. Why wasn't that enough to skip ahead?
Those earlier results weren't from formal clinical trials. They were observations from research settings without the controls and documentation that regulators require. You need to prove it works in a systematic way, with proper measurement and oversight. That's what the trials are for.
What happens if Phase 1 is successful? How long until patients can actually get this drug?
If safety is confirmed, they'd move to Phase 2 and Phase 3 trials to measure efficacy and refine dosing. That could take years. But the fact that Anvisa created an expedited pathway for this suggests they recognize the medical need is urgent. Spinal cord injuries are devastating, and there are almost no treatments. That pressure might accelerate things.
Why is this a Brazilian drug? What's special about the research being done in Rio?
The Federal University of Rio has been studying this compound for over 20 years. That's a long institutional commitment. The research foundation in Rio has funded it consistently. And now a Brazilian pharmaceutical company is partnering on it. It's not that Brazil invented nerve regeneration—it's that this particular team has been pursuing this particular approach longer than most.